In this study, we observed notable differences in clinical characteristics, inflammatory markers, and severity scores between patients with MAP and those with MS-SAP, with the neutrophil CD64 index (nCD64) standing out as a particularly rapid, convenient, and reliable marker for assessing disease severity and prognosis. Here, FCGR1A is linked to myeloid sarcoma.